Dr. Afeyan is Managing Partner and CEO of Flagship Ventures, a firm that manages over $900 million in early-stage funds across the sectors of Therapeutics, Health Technologies and Sustainability/Clean Technology. A technologist, entrepreneur and venture capitalist, Dr. Afeyan has co-founded and helped build over 25 successful life science and technology start-ups during the past two decades. In addition to Joule, he is a director and co-founder of Flagship portfolio companies Affinnova, BG Medicine, Ensemble Therapeutics, LS9, Midori, Moderna Therapeutics and Pronutria. Previously he was a member of the founding team, director and investor in several successful ventures including Chemgenics Pharmaceuticals, Color Kinetics, Antigenics, EXACT Sciences and Adnexus Therapeutics.
Dr. Snaith joined Joule in 2012 to lead business development strategy, and was later appointed as the company's Chief Business Officer and Chief Operating Officer, respectively. He previously held multiple roles at Shell over the course of 24 years, most recently serving as Vice President, Downstream Marketing for Shell Global Solutions and as Managing Director of Shell Research, Ltd. During that time his responsibilities included leading the technology strategy for Shell's biofuels business. His prior positions with the company spanned senior leadership roles across multiple Shell businesses and regions, including: Lubricant Product Manager in France; Global Fuels Management roles in the UK; Sales and Marketing Director in Oman; General Manager for Shell's LPG businesses in the Mediterranean, African and South American regions; and Marketing Vice President for the global LPG business. Dr. Snaith holds a PhD and BSc in Biological Sciences from Lancaster University and is a Fellow of the Royal Society of Chemistry.
Dr. Anton joined Joule in 2014 to lead the transition of the company's technology to commercialization. His relevant experience spans nearly 30 years, including five years at Codexis where he served as Senior Vice President of Bioindustrials, Chief Technology Officer and Senior Vice President of Process Development & Manufacturing. During his tenure, he oversaw development and commercial application of the company's bioindustrial platform and led the global R&D manufacturing organization. Dr. Anton previously spent 25 years at DuPont in multiple senior management positions across bioprocessing and biocatalysis, including the role of global business lead for development of DuPont's advanced biofuel. He holds a BS in Biochemistry from the University of California, Berkeley and a PhD in Biochemistry from the University of Minnesota.
Dr. Robertson has led the bioscience efforts at Joule since its inception in 2007. Prior to Joule, he served as Director of Enzymology at Diversa Corporation and as Vice President of Biofuels R&D for Verenium, where he led the development of microbial strains for cellulosic ethanol production. In addition to his 14 years of industrial experience, Dr. Robertson also has a 14-year academic background focused on the energetics of membrane transport and photosynthesis. He received his PhD degree in Biochemistry from the University of Pittsburgh.
Mr. Solakian is a seasoned general counsel and corporate executive with 20 years experience in public and private company matters. He was previously Senior Vice President, General Counsel and Corporate Secretary at Helicos BioSciences Corporation, where he was responsible for all legal affairs through the company’s successful IPO, multiple financings, strategic partnerships and corporate restructurings. Prior to Helicos he was Vice President and Chief Corporate Counsel at Affymetrix, Inc., a publicly-traded life sciences company where he oversaw all corporate legal matters. Mr. Solakian was a business law attorney at Goodwin Procter LLP in Boston prior to joining Affymetrix. He holds an AB degree from Harvard University and a JD degree from Boston College Law School.
Mr. St. Angelo has a successful track record spanning 20+ years in engineering, including leadership roles in the clean tech and energy industries. He was previously Vice President of Engineering at Skyonic Corporation, where he led the initial conceptualization and development of patented technology for the capture and conversion of carbon into mineral products. Prior to Skyonic, he was Vice President of Large Format Energy Solutions at Valence Technology, Inc., a developer of low-cost energy storage systems using lithium-ion batteries. In that role he led the definition, design, development and commercialization of the division’s large format product line, while also implementing and managing the company’s licensing program. Mr. St. Angelo holds a BS degree in Chemical Engineering from the University of Massachusetts/Amherst and a MS degree in Electrical Engineering from Northeastern University.
Mr. Ward has led the design, construction, validation and operations of biopharmaceutical facilities for more than 20 years. Prior to Joule, he served as VP of Engineering and Facilities at Biogen Idec, a $4 billion biotechnology company where he held global responsibility for engineering, construction, validation, facilities management, and environmental, health, safety and security, among other functions. He holds an MBA from the Stephen M. Ross School of Business at the University of Michigan, BE and ME degrees in Chemical/Biochemical Engineering from Dartmouth College, and an AB in Physics from Hamilton College.
Mr. Hillery is an accomplished financial executive with 30 years of experience, including senior roles managing the finance, accounting and tax functions of global technology companies. Prior to Joule, he was Vice President, Finance at QD Vision, Inc., a nanomaterials company that emerged from start-up to commercialization during his tenure. Prior to QD Vision, he was Vice President, Finance and Controller at Color Kinetics, a LED-lighting company, during a high-growth period that spanned the company's IPO through its sale to Philips for $800 million. Earlier in his career, Mr. Hillery was a practicing Certified Public Accountant rising to Senior Audit Manager at Deloitte & Touche LLP. He holds a BS in Accounting from Bentley College.
Ms. Cloghessy has more than 15 years experience building and leading HR programs for large, growing, advancing organizations within the biotech, pharmaceuticals and life sciences industries. Prior to joining Joule, she served as Senior Director of Human Resources for Interleukin Genetics, where she built the human resources function from the ground up, implemented progressive practices to attract and retain top talent, achieve market competitiveness and support organizational development. She previously held senior HR roles at NUCRYST Pharmaceuticals and the Immune Disease Institute (formerly CBR Institute for Biomedical Research), a Harvard Medical School affiliate. Ms. Cloghessy holds a BA in Psychology from the University of Massachusetts and professional SPHR certification in the field of human resources.
Mr. Glacken's expertise in bioprocess development derives from 15 years of industrial and academic experience. Prior to joining Joule, he served as Site Director for Bioprocess Development at Millennium Pharmaceuticals. He has worked or consulted for biopharmaceutical companies ranging from large to small, including SmithKline Beecham, Bristol-Myers Squibb, Genentech, Genzyme Transgenics, Dow Agrosciences and SemBioSys. He was previously Assistant Professor of Chemical Engineering at Rice University. Mr. Glacken holds a BS degree in Chemical Engineering from the University of Maryland and an ScD degree in Biochemical Engineering from MIT.
Mr. Hong leads Joule's intellectual property development, strategy and implementation. Prior to Joule, he served as IP Counsel to companies including Emergent Biosolutions, Pliva (Teva) and GlycoFi (Merck), where he counseled senior management on developing IP strategy and portfolios, assessment of third-party rights and Hatch-Waxman litigation as well as due diligence, licensing and contract matters. Mr. Hong received a JD/LLM in Intellectual Property from Franklin Pierce Law Center and a BS in Biochemistry & Molecular Biology and Music from Dickinson College.
Dr. Madden is a 13-year veteran of the biotechnology industry, with expertise in the production of renewable fuels and pharmaceutical products. He was previously Chief Scientific Officer at Microbia, Inc. (now a subsidiary of Royal DSM), where he led the company's innovation from the R&D stages through the commercialization of numerous products. He also developed and managed 14 partnerships across multiple markets, and was instrumental in building and managing the company's intellectual property portfolio. Prior to Microbia, Dr. Madden was a Postdoctoral Fellow at Millennium Pharmaceuticals. His research has received several acknowledgments, including a Howard Hughes Medical Institute Predoctoral Fellowship. He holds a BA in Biology from the University of Pennsylvania and PhD in Biology from Yale University.